Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
CAS NO.168273-06-1
1. We have experience in exporting steroids, as you know, EU places much emphasis on them, and you must find a experienced partner who will assure you;
2. Quality: Our company is a professional leading factory in China in pharmaceutical area, We had stable customers and exported to Germany, Spain, UK, USA, Australia, Middle East, and any other countries. We can provide good references about our company. As for the quality of the products, we 're sure they can satisfy you well enough;
3. Package: Professional packing with professional materials
4. Delivery: We have products in stock, and we will deliver them soon when your PO arrived.
Meanwhile we will give you the tracking number in order to make you know the exact location of the products. We will keep track of the product until they arrive you; We choose the best courier service for you, and with the delivery around 4-7 working days.
5. Service: Best Service with after-sales service and consultation.
Description
Rimonabant Product name : Rimonabant
Rimonabant Other name : ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716)
Rimonabant CAS : 168273-06-1
Rimonabant MF : C22H21Cl3N4O
Rimonabant MW: 463.79
Rimonabant Assay : 99%
Rimonabant Appearance:White Powder
Usage : Weight loss powders/ Rimonabant is a selective antagonist
Rimonabant is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet. It was not recommended for those who just wanted to lose a few pounds. Rimonabant is valuable in smoking cessation therapy, and initial results are positive.
Applications;
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Rimonabant works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
Specification
Test Items |
Specification |
Test Results |
Description |
White crystalline powder |
White crystalline powder |
Identification |
IR , UV conform |
Conform |
Loss on drying |
≤0.5ml |
0.21ml |
Residue on ignition |
Not more than 0.2% |
0.06ml |
Iron |
Not more than 0.005% |
0.0018% |
Heavy metals |
Not more than 0.001% |
0.0006% |
Related substances |
Total: Not more than 1.0% |
0.32% |
E-isomer |
Not more than 0.3% |
0.19% |
Organic volatile impurities |
Conforms |
Conforms |
Assay |
99.0~101.0% |
99.51% |
Conclusion |
Conform with USP30 |
An experimental wonder drug, Rimonabant, helps you lose weight, quit smoking and it also helps protect your heart. Trials have shown that 33% of people on Rimonabant lost 10% of body weight and kept their weight down for two years - this is a record, no other diet drug has managed to keep a person's weight down for so long. The second 33% lost 5% of body weight and kept it down. As well as keeping you lean, the drug also helps you quit the smoking habit. This will be of great interest for many smokers who are afraid to give up because they say they will put on loads of weight if they do
Rimonabant Application:
1) Obesity
In a 2006 (2 year) study reported in JAMA, "Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (-6.3 [0.2] kg vs -1.6 [0.2] kg; P<.001), waist circumference (-6.1 [0.2] cm vs -2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, -5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001)." [12]
2) Smoking cessation
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects.
Stratus is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy.